Please find attached outcome of Board Meeting.

Date: August 05, 2026 BSE Limited Department of Corporate Services 25th Floor, P J Towers, Dalal Street, Mumbai – 400001 BSE Scrip Code: 542934 Subject: Outcome of the meeting of Board of Directors pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 In continuation to our letter date July 30, 2026 and pursuant to regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Chandra Bhagat Pharma Limited (‘the Company’) at its meeting held today i.e., Wednesday, August 05, 2026, has considered and approved, inter alia, following agenda items: 1. Increase in the Authorised share capital of the Company from existing Rs. 8,50,00,000/- (Rupees Eight Crores Fifty Lakhs only) divided into 85,00,000 (Eighty-Five Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each to Rs. 15,00,00,000/- (Rupees Fifteen Crore only) divided into 1,50,00,000 (One Crore Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each by creation of additional Rs. 6,50,00,000/- (Rupees Six Crore Fifty Lakhs only) divided into 65,00,000 (Sixty-Five Lakhs) Equity shares of Rs. 10/- (Rupees Ten only) each subject to approval of shareholders in the ensuing general meeting of the Company; 2. Issue of up to 66,00,000 Convertible Warrants at an issue price of Rs. 44/- each including a premium of Rs. 34/- each to the promoters & non-promoters on preferential basis, subject to approval of shareholders in the ensuing general meeting of the Company; 3. Directors’ Report of Company for the financial year ended on 31st March, 2026; 4. Notice of Annual General Meeting (AGM) of the Members of the Company scheduled to be held on Tuesday, September 01, 2026 at 04:00 P.M. at the Registered Office of the Company. 5. Appointment of M/s. Amit Dharmani & Associates, Company Secretaries as scrutiniser for scrutinising the voting and issuance of Scrutinizer Report to the Company. The additional details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 are enclosed as Annexure – I. The Meeting of the Board of Directors of the Company commenced at 04:00 P.M. IST and concluded at 04:40 P.M. IST. This is for your perusal and records. Thanking you, Your faithfully Chandra Bhagat Pharma Limited Hemant Chandravadan Bhagat Managing Director DIN: 00233530 ANNEXURE – I Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 for Issue of Convertible Warrants on Preferential basis of Company: S. PARTICULARS DETAILS 1. Ty pe of securities proposed Convertible Warrants to be issued 2. Ty pe of issuance Preferential Issue under Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 3. To tal number of Convertible Warrants: 66,00,000 (Sixty-Six Lakh) securities proposed to be (Detailed list of allottees is mentioned hereunder) issued 4. To tal amount for which the Convertible Warrants: Total amount is aggregating up securities will be issued to Rs. 29,04,00,000/-. 5. Po st allotment of securities-  Issue price of the Convertible Warrants of Rs. outcome of the subscription, 44/- (Rupees Forty-Four only) each including issue price/ allotted price (in a premium of Rs. 34/- (Rupees Thirty-Four case of convertibles), only). The issue price is not lower than the number of investors floor price determined in accordance with the Regulation 164 & 166A of Chapter V of SEBI In case of convertibles – ICDR Regulations. intimation on conversion of securities or on the lapse of Minimum 25% of the price of the Warrant the tenure of the instrument would be payable upfront at the time of application and the balance 75% shall be payable at the time of conversion of the warrants into Equity Shares of the Company.  Total number of Investors: 9 (Nine).  Conversion ratio of each Convertible Warrant: Each Warrant can be converted into 1 (One) Equity Share of the Company and conversion can be exercised at any time within a period of 18 months from the date of allotment of Warrants, in one or more tranches as the case may be and on such other terms and conditions as applicable. In case the investor fails to exercise the same within the stipulated period, the warrants shall lapse. The issuance of upto 66,00,000 Convertible Warrants is subject to the approval of members by way of passing special resolution at the Annual General Meeting to be held on Tuesday, September 01, 2026. LIST OF INVESTORS FOR CONVERTIBLE WARRANTS: Sr. Name of the Pre- No. of Current Proposed No. Proposed Allottees Holding Convertible Status / Status / Shares Warrants to Category Category be allotted 1. Hemant Chandravadan 26,78,296 5,00,000 Promoter Promoter Bhagat 2. Chitra Hemant Bhagat 12,33,192 5,00,000 Promoter Promoter Group Group 3. Pranav Hemant Bhagat 7,61,792 10,00,000 Promoter Promoter 4. Prachi Pranav Bhagat 4,03,600 9,50,000 Promoter Promoter Group Group 5. Mahesh C Bhagat 1,20,000 7,00,000 Promoter Promoter Group Group 6. Jay Hemant Bhagat 83,600 7,00,000 Promoter Promoter Group Group 7. Lopa Mahesh Bhagat 8,000 6,50,000 Promoter Promoter Group Group 8. Samir Ramakant Dave - 8,00,000 Non- Non- promoter promoter 9. Chintan Vijay - 8,00,000 Non- Non- Makhecha promoter promoter